Arax Advisory Partners’s Takeda Pharmaceutical TAK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $88.4K | Buy |
773
+539
| +230% | +$61.6K | ﹤0.01% | 984 |
|
|
2025
Q1 | $3.48K | Buy |
+234
| New | +$3.48K | ﹤0.01% | 1914 |
|
|
2024
Q4 | – | Sell |
-1,556
| Closed | -$22.1K | – | 2738 |
|
|
2024
Q3 | $22.1K | Sell |
1,556
-358
| -19% | -$5.09K | ﹤0.01% | 1043 |
|
|
2024
Q2 | $24.8K | Sell |
1,914
-42
| -2% | -$544 | ﹤0.01% | 901 |
|
|
2024
Q1 | $27.2K | Buy |
1,956
+420
| +27% | +$5.84K | ﹤0.01% | 616 |
|
|
2023
Q4 | $21.9K | Buy |
1,536
+4
| +0.3% | +$57 | ﹤0.01% | 634 |
|
|
2023
Q3 | $23.7K | Sell |
1,532
-32
| -2% | -$495 | ﹤0.01% | 557 |
|
|
2023
Q2 | $24.6K | Buy |
1,564
+412
| +36% | +$6.47K | ﹤0.01% | 554 |
|
|
2023
Q1 | $19K | Buy |
+1,152
| New | +$19K | ﹤0.01% | 593 |
|
|
2022
Q2 | – | Sell |
-201
| Closed | -$3K | – | 1238 |
|
|
2022
Q1 | $3K | Buy |
201
+100
| +99% | +$1.49K | ﹤0.01% | 899 |
|
|
2021
Q4 | $1K | Buy |
+101
| New | +$1K | ﹤0.01% | 1086 |
|
|
2021
Q3 | – | Sell |
-2,372
| Closed | -$40K | – | 1071 |
|
|
2021
Q2 | $40K | Buy |
+2,372
| New | +$40K | 0.01% | 499 |
|
|
2020
Q4 | $40K | Hold |
2,200
| – | – | 0.01% | 438 |
|
|
2020
Q3 | $39K | Hold |
2,200
| – | – | 0.01% | 417 |
|
|
2020
Q2 | $39K | Hold |
2,200
| – | – | 0.01% | 402 |
|
|
2020
Q1 | $33K | Hold |
2,200
| – | – | 0.01% | 403 |
|
|
2019
Q4 | $43K | Hold |
2,200
| – | – | 0.01% | 356 |
|
|
2019
Q3 | $38K | Buy |
2,200
+1,000
| +83% | +$17.3K | 0.01% | 362 |
|
|
2019
Q2 | $21K | Buy |
+1,200
| New | +$21K | 0.01% | 405 |
|
|
2018
Q4 | $20K | Buy |
+1,200
| New | +$20K | 0.01% | 368 |
|